Cargando…
Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy
Immunocheckpoint inhibitors have shown significant efficacy in the treatment of hepatocellular carcinoma (HCC), but there are individual differences. The aim of this study was to explore body mass index (BMI) as a predictor of anti-PD-1 efficacy in patients with HCC. We retrospectively analyzed 101...
Autores principales: | Chen, Jierong, Lu, Lianghe, Qu, Chunhua, A, Gari, Deng, Fangqi, Cai, Muyan, Chen, Wei, Zheng, Lie, Chen, Jiewei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530364/ https://www.ncbi.nlm.nih.gov/pubmed/36203764 http://dx.doi.org/10.3389/fmed.2022.981001 |
Ejemplares similares
-
Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma
por: Zhang, Xinke, et al.
Publicado: (2022) -
Immune Microenvironment Characteristics of Urachal Carcinoma and Its Implications for Prognosis and Immunotherapy
por: Zhang, Xinke, et al.
Publicado: (2022) -
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures
por: Zhang, Xinke, et al.
Publicado: (2021) -
Body Mass Index and Waistline are Predictors of Survival for Hepatocellular Carcinoma After Hepatectomy
por: Liu, Xiyu, et al.
Publicado: (2015) -
Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
por: Chen, Jiewei, et al.
Publicado: (2018)